ThromboGenics News
Most Popular ThromboGenics Story
Roche signs up for $774M development pact
Roche has forged a $774 million deal to license an early stage cancer drug from Belgium's ThromboGenics and Sweden's BioInvent. In the deal, ThromboGenics gets a whopping $77.4 million upfront Read more...
Latest Headlines
- March 11, 2011
- August 29, 2008
- June 30, 2008
- June 18, 2008
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
